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Dengue virus (DENV) threatens almost 70% of the world’s population, with no therapeutic
currently available. The severe, potentially lethal forms of DENV disease (dengue
hemorrhagic fever/dengue shock syndrome) are associated with the production of high
level of cytokines, elicited as part of the host antiviral response, although the molecular
mechanisms have not been fully elucidated. We previously showed that infection by
DENV serotype 2 (DENV2) disrupts promyelocytic leukemia (PML) gene product nuclear
bodies (PML-NBs) after viral protein translation in infected cells. Apart from playing a
key role as the nucleating agent in forming PML-NBs, PML has antiviral activity against
various viruses, including DENV. The present study builds on this work, showing for the
first time that all four DENV serotypes elicit PML-NB breakdown. Importantly, we show
for the first time that of the nuclear localizing proteins of DENV, DENV non-structural
protein (NS) 5 polymerase alone is sufficient to elicit PML-NB disassembly, in part through
complexing with PML isoforms III and IV, but not other PML isoforms or other PML-NB
components. The results raise the possibility that PML-NB disruption by nuclear localized
NS5 contributes to DENV’s suppression of the host antiviral response.
Keywords: dengue virus, non-structural protein 5 polymerase, promyelocytic leukemia protein, PML-NBs
disruption, PML isoform
INTRODUCTION
Dengue virus (DENV), a member of the genus Flavivirus within the family Flaviviridae, is the
most significant cause of arthropod-borne viral disease in humans (Bhatt et al., 2013). DENV has
a single, positive-stranded RNA genome of approximately 11 kb, with a single long open reading
frame translated as a poly-protein, which is subsequently cleaved by a combination of cellular signal
peptidases and the virally encoded protease NS2B/NS3 to yield three structural (C, prM and E) and
seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) (Ngono and
Shresta, 2018).
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Several positive-strand RNA viruses, including DENV,
although replicating exclusively in the cytosol seemingly not
requiring any nuclear intermediaries, interact with the host
nucleus/host components of the nucleus (Weidman et al., 2003;
Caly et al., 2015; Audsley et al., 2016; Jans and Martin, 2018) as
part of the viral strategy to antagonize the host antiviral response.
Viruses achieve this either by sequestering nuclear factors and/or
trafficking their own proteins into the nucleus to impact host
gene expression, and thereby attenuate the antiviral response
(Hiscox, 2003; Caly et al., 2015; Audsley et al., 2016; Jans and
Martin, 2018).
Three DENV viral proteins have been reported to access the
host nucleus in infected cells. Of these, C (Tadano et al., 1989;
Sangiambut et al., 2008) and NS5 (Pryor et al., 2007; Fraser et al.,
2016) are known to localize in the infected cell nucleus, while NS3
was recently reported to be present in the host nucleus (Reyes-
Ruiz et al., 2018). The polymerase NS5 is the largest (105 kDa)
and most conserved protein encoded by the DENV genome,
with critical roles in viral RNA synthesis through localization
in membrane-associated replicase complexes in the cytoplasm
of infected cells (Welsch et al., 2009). It has also been shown to
shuttle between the nucleus and the cytoplasm antagonizing the
antiviral response, by modulating IL-8 production and mRNA
splicing in infected cells (Medin et al., 2005; Pryor et al., 2007;
Ashour et al., 2009; Rawlinson et al., 2009; Morrison et al., 2013;
DeMaio et al., 2016); importantly, preventing NS5 nuclear access
by small molecule inhibitors or mutation reduces infectious virus
production significantly (Pryor et al., 2007; Wagstaff et al., 2012;
Tay et al., 2013; Fraser et al., 2014).
Promyelocytic leukemia protein (PML) nuclear bodies (PML-
NBs) are discrete punctate structures within the nucleus of
mammalian cells. Although a small number of core proteins
define the PML-NB (PML, DAXX, SP100, SUMO1-3), more than
100 other proteins have been reported to localize to PML-NBs in
dynamic fashion (Van Damme et al., 2010), with certain PML-
NB components known to undergo continuous exchange with
the surrounding nucleoplasm (Weidtkamp-Peters et al., 2008).
Significantly, the composition and morphology of PML-NBs can
vary in response to cellular stress and virus infection (Dellaire and
Bazett-Jones, 2004; Scherer and Stamminger, 2016), consistent
with PML-NBs playing a role in key cellular functions, including
the antiviral response (Hoischen et al., 2018).
Alternative splicing results in six major isoforms of the
primary PML gene transcript, all of which localize in PML-
NBs when overexpressed. Although all PML isoforms contain a
conserved N-terminal region consisting of the RING, B-boxes,
coiled-coil (RBCC) motifs, and the SUMO binding domain
(SBD), differences in the C-terminal regions (Fagioli et al., 1992;
Jensen et al., 2001; Nisole et al., 2013) are presumably the
basis of isoform-specific roles. Various viruses are known to
target specific isoforms (Nisole et al., 2013; Atwan et al., 2016),
consistent with the idea that PML-NBs play key roles in the
antiviral response (Scherer and Stamminger, 2016). The antiviral
activity of PML-NBs has been shown for DNA viruses, for
example, many of which alter/disorganize PML-NBs (Guccione
et al., 2004; Geoffroy and Chelbi-Alix, 2011). Although less well
studied, RNA viruses, some of which are of public health concern,
have also been reported to use different strategies to counteract
PML’s antiviral function (Borden et al., 1998; Blondel et al., 2002;
El McHichi et al., 2010).
We previously showed that PML appears to play an antiviral
activity toward DENV-2 (Giovannoni et al., 2015). Here, we
extend these studies to show for the first time that infection by all
4 DENV serotypes impacts on PML-NB structure, establishing
that of the nuclear localizing DENV proteins, NS5 proteins but
not NS3 or C are responsible, and that PML isoforms III and
IV, but not other PML isoforms or PML-NB components, are
the targets of NS5 action. Importantly, we show that PML-
NB disruption by nuclear localized NS5 contributes to DENV
suppression of the host antiviral response. This is the first report
to highlight the key role of PML-NBs, through the NS5-PML
III/IV interface, in DENV infection.
RESULTS
PML Is an Antiviral Host Factor for All
DENV Serotypes
We previously reported that PML plays an antiviral role in
infection by DENV-2 (Giovannoni et al., 2015). Here we set out
to extend this work, initially using siRNA to test the importance
of PML for infection by other serotypes of DENV. To this
end, cultures of A549 cells were treated with siRNA specific
to PML or control scrambled siRNA and then infected with
DENV-1-4, prior to determination of virus yields 48 h later using
plaque assays. PML knock-down resulted in significantly (p <
0.05) higher infectious virus production for all DENV serotypes
compared to the scrambled siRNA controls (Figure 1A). The
infected cell cultures were also analyzed by confocal microscopy,
with maximum intensity projections generated from Z-stacks
(Figure 1B) enabling the number of PML-NBs per nucleus to
be quantified (Figure 1C). In the case of all DENV serotypes,
infection was found to significantly (p< 0.01) reduce the number
of PML-NBs by∼2-fold (Figure 1C).
DENV NS5 Is Sufficient to Promote
PML-NB Disruption
The DENV genome encodes three proteins (C, NS3, and NS5)
that are able to localize in the nucleus of infected cells. In order
to determine whether any of these may be directly responsible
for the effects on PML-NBs, A549 cells were transfected to
express green fluorescent protein (GFP)-tagged (NS3, NS5) or
untagged (C protein) versions of the proteins derived from
DENV-2. A vector expressing GFP fused to a nuclear localization
signal (nls-GFP) that can localize in the nucleus served as
a control. Confocal imaging (Figure 2A) revealed that the
pattern of PML-NBs was not affected in cells expressing C,
GFP-NS3, or nls-GFP, in stark contrast to cells expressing
GFP-NS5, which showed significantly (p < 0.01) reduced
numbers (70% lower—Figures 2A,B).
The number of PML-NBs was also analyzed in cell cultures
transfected to express NS5-GFP proteins from the other DENV
serotypes (Figure 3). GFP-tagged NS5 from DENV-1 and−4
was found in both cytoplasm and nucleus, whereas NS5 from
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FIGURE 1 | Infection with all 4 DENV serotypes can disrupt host cell PML-NBs. (A) A549 cells were transfected with PML-siRNAs or X-siRNAs (scrambled sequence)
and then infected with one of DENV1-4 (MOI of 1) as indicated. Culture supernatants were harvested at 48 h post-infection (p.i.) and infectious virus particles
quantified by plaque assay. Data represent the mean ± SD from three independent experiments. *p < 0.05;
(Continued)
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FIGURE 1 | **p < 0.01 (Student’s t test). (B) A549 cells were mock-infected or infected with one of the four DENV serotypes as indicated. Cells were fixed and
stained at 48 h p.i. against DENV envelope glycoprotein E (green) and PML (red). Confocal images were acquired using an Olympus FV1000 setup. Differential
interference contrast (DIC) images are shown on the left. Scale Bar: 20µm. (C) Quantification of the average number of PML-NBs per nucleus was performed using
FIJI. At least 50 cells per condition and per experiment were quantified. Data represent the mean ± SD from three independent experiments. **p < 0.01 (one-way
ANOVA followed by Tukey’s post-hoc test).
DENV-2 and−3 was mainly nuclear, indicative of quantitative
differences between DENV1-4 in the extent of NS5 nuclear
localization (Figure 3A), in agreement with previous studies (Tay
et al., 2013). Importantly, expression of NS5 from any of the four
DENV serotypes significantly (p < 0.05) reduced the number
of PML-NBs by about 70% compared to untransfected cells or
those expressing nls-GFP (Figure 3B). Thus, NS5 from all 4
DENV serotypes is sufficient to disrupt PML-NBs even out of
the context of the infected cell, indicating conservation of this
property across all of the DENV serotypes.
To assess association of NS5 with PML, we used PML
specific antibodies to perform co-immunoprecipitation from
cell lysates prepared from A549 cells infected with DENV-2
(Figure 3C). Precipitates were extensively washed, and then
eluates electrophoresed and subjected to Western blot analysis
using anti-NS5 specific antibodies. Figure 3C shows that anti-
PML antibodies were able to pull-down NS5 from the infected
cell lysates but not from mock-infected cells (Figure 3C,
compare lanes 4 and 3, respectively), with an electrophoretic
band for the complex of PML and NS5 at the predicted
molecular weight of ca. 170 kDa., indicating the viral protein
is interacting with an specific PML isoform. Given the
molecular weight of NS5 (95 kDa), complexation of PMLIII,
IV, or V and NS5 may represent a key step for subsequent
disassembly of PML-NBs.
PML Isoforms III and IV Specifically Recruit
NS5 Into NBs
To assess which of the six nuclear PML isoforms (PML-I-
VI) may be instrumental to attract NS5 into PML-NBs, A549
cells were co-transfected to express DENV-2 NS5-GFP together
with one of PML isoforms I-VI fused to monomeric Red
Fluorescent Protein (mRFP-PML), and observed by confocal
microscopy. As shown in Figure 4, minimal co-localization
was observed between NS5-GFP and mRFP-PML-I, -PML-II,
-PML-V, or -PML-VI. In contrast, mRFP-PML-III and -PML-
IV showed strong co-localization in PML-NBs (Figure 4A);
this was supported by quantitative analysis for Pearson’s
co-localization coefficient, which revealed values approaching
0.7, compared to the other isoforms where the value was
below 0.4 (Figure 4B).
In order to gain a more quantitative estimate of the co-
localization, we compared NS5 recruitment by PML-III and
-IV with that of overexpressed nls-GFP alone. As above,
ectopic expression of either PML-III or -IV induced the
accumulation of NS5-GFP in large PML-NB structures, in
contrast to the discrete punctate pattern observed in the presence
of co-expressed nls-GFP, which was diffusely nucleoplasmic
(Figure 5A). Quantitative analysis showed that the average
area of PML-NBs containing GFP-NS5 was significantly (p <
0.01) higher (3–4-fold) in cells co-expressing PML-III or -IV
than in those co-expressing nls-GFP (Figure 5B). Importantly,
significantly (p < 0.01) increased co-localization of (ca. 2-fold)
NS5 and PML-III or –IV compared to nls-GFP was evident, as
indicated by the estimation of Pearson’s coefficient (Figure 5C).
As negative controls, cells were also co-transfected to express
NS5-GFP along with vectors encoding mCherry-tagged DAXX
or SP100 (constitutive PML-NB components); there was no
accumulation of NS5-GFP in PML-NBs in mCherry-SP100 or
-DAXX overexpressing cells (Figures 5D,E). This is consistent
with the idea that NB recruitment of NS5-GFP by the PML-
III and IV isoforms is specific, and not a property of PML-NB
components generally.
Effect of NS5 Expression on PML Protein
Levels
Next, we assessed the effect of NS5 expression on ectopically
expressed PML protein levels in cells treated with the translation
inhibitor cycloheximide. Cycloheximide induced a decrease in
PML-III and –IV levels after about 6–8 h of treatment; NS5
co-expression appeared to accelerate this effect, with decreased
PML-III and -IV levels after 4 h of treatment (Figure 6). This
reduction in PML-III and -IV levels appeared to be independent
of protein translation, suggesting that NS5 actively increases
PML turnover.
PML III and IV Inhibit DENV Replication
To put our results in physiological context, we tested the effect
of ectopic expression of specific PML isoforms on DENV-2
infection. HEK-293 cells, extensively used in flavivirus research
because of their ease of transfection and permissiveness to
DENV infection (Chan and Gack, 2016; Aguirre et al., 2017),
were transfected to express one of PML isoforms I-VI fused
to RFP. 48 h later, cells were infected with DENV-2 (MOI =
1) and fixed 48 h post-infection, prior to immunofluorescence
against the viral antigen E to assess viral replication. Figure 6A
shows that HEK-293 cells ectopically expressing either RFP-
tagged PML-III or -IV displayed a marked decrease in the
expression of DENV-2 viral antigen compared to non-transfected
or nls-GFP expressing cells. Overexpression of other PML
isoforms or PML associated components DAXX or SP100 did
not alter viral antigen expression. Cell culture supernatants were
harvested to determine infectious virus production. Figure 6B
shows that cells transfected with nls-GFP had a viral particle
production similar to that of non-transfected cells. Ectopic
expression of PML-I, -II, -V, -VI, or DAXX or SP100 did not
significantly impact infectious virus production. In contrast,
ectopic expression of either PML-III or -IV significantly
(p < 0.01) decreased viral yield by 60% compared to the
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FIGURE 2 | Ectopically expressed DENV-2 NS5 is sufficient to mediate PML-NBs disassembly. (A) A549 cells were mock-transfected or transfected with plasmids
encoding nls-GFP, DENV-2C, DENV-2 NS3-GFP, or DENV-2 NS5-GFP (all green) as indicated. 24 h later, cells were fixed and stained for PML (red), and where
appropriate, for C (green). Confocal images were acquired using a Zeiss LSM710 setup. Scale Bar: 10µm. (B) Quantification of the average number of PML-NBs per
nucleus was performed using FIJI. At least 50 cells per condition and per experiment were quantified. Data represent the mean ± SD from three independent
experiments. Ns, not statistically significant; **p < 0.01 (one-way ANOVA followed by Tukey’s post-hoc test).
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FIGURE 3 | NS5 from DENV1-4 is sufficient to mediate PML-NBs disassembly. (A) A549 cells were transfected with plasmids encoding for NS5-GFP of DENV1-4
(green). 24 h later, cells were fixed and stained for PML (red). Images of optical sections were acquired using a Zeiss Apotome.2 setup. Scale Bar: 10µm.
(Continued)
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FIGURE 3 | (B) Quantification of the average number of PML-NBs per nucleus was as per the legend to Figure 2B. ns, not statistically significant; *p < 0.05;
**p < 0.01 (one-way ANOVA followed by Tukey’s post-hoc test). (C) A549 cells were mock-infected or infected with DENV-2 and 48 h p.i. they were harvested for
immunoprecipitation against PML followed by Western blot against DENV-2 NS5. Lanes 1 and 2 correspond to whole cell lysates (Input) and 3 and 4 correspond to
precipitates (IP). Images are representative of three independent experiments.
control (Figure 6B). These results strongly imply that PML
isoforms III and IV, but not the other PML isoforms or
PML components, appear to have specific antiviral activity
toward DENV.
DISCUSSION
Collectively, our results show for the first time that PML
exerts antiviral activity against all 4 DENV serotypes, underlying
PML’s importance as an antiviral host factor in the case
of infection by DENV. In particular, significant increments
of viral yield in PML knock down infected cell cultures
were detected (Figure 1A). In line with our previous results,
microscopic observations revealed that PML-NBs are disrupted
after DENV infection (Figures 1B,C), implying that DENV-
induced PML-NB disruption may be a strategy to circumvent
this cellular restriction point. Indeed, we show that expression
of NS5 alone is sufficient to disrupt PML-NBs (Figures 2,
3A,B). Significantly, a complex between endogenous PML and
NS5 could be detected in infected cell lysates (Figure 3C),
which may represent a key step for PML-NB disassembly.
Strikingly, PML-III and –IV showed localization in much larger
nuclear bodies in the presence than in the absence of NS5,
in contrast to other PML isoforms. These observations suggest
that PML isoforms III and IV may uniquely recruit NS5
into PML-NBs, and/or alter PML-NB structure/composition
(Figures 4, 5). In fact, degradation of PML after NS5 transfection
was observed by different approaches confirming NS5 as
the counteracting viral protein for PML antiviral activity
(Figures 3, 6). Finally, we found that PML-III and –IV, but
not other PML isoforms or other components of PML-NB,
act to reduce infectious virus production (Figure 7). PML-
IV has been implicated in the restriction of viruses such
as the encephalomyocarditis virus, where it sequesters the
viral polymerase in PML-NBs, thereby blocking its activity
(Maroui et al., 2011), and varicella-zoster virus (Reichelt et al.,
2011), where PML IV uniquely sequesters the viral capsid
protein into PML-NBs. Whether PML exerts its antiviral
effect against DENV through sequestering NS5 in PML-NBs
and preventing replication remains to be determined. Clearly,
however, NS5’s role in targeting PMLIII/IV and thereby PML-
NBs seems highly significant for the evasion of intrinsic
and innate immunity.
The concept of intrinsic immunity was first introduced in
2004 (Bieniasz, 2004). It was proposed to be mediated by
host restriction factors, constitutively expressed proteins with
antiviral activity (Kluge et al., 2015). Restriction factors have been
proposed to fulfill four main criteria (Duggal and Emerman,
2012); it must restrict virus production, the virus must have a
strategy to circumvent it, it must be IFN induced, and its gene
must show evidence of positive selection. Although the PML
gene does not show evidence of positive selection (Malfavon-
Borja et al., 2013), we have previously shown that it both
exerts an antiviral effect against DENV and is induced by IFN
(Giovannoni et al., 2015). The results here formally confirm that
PML’s antiviral activity is counteracted by a viral protein (NS5).
Clearly, irrespective of whether PML can be formally delineated
as a host restriction factor for viral infection in this context, PML
is clearly an interesting candidate for the development of future
therapies against DENV and potentially other flaviviruses.
MATERIALS AND METHODS
Cells and Viruses
A549 (ATCC, CCL-185) and Vero (ATCC, CCL-81) cells
were grown in Eagle’s minimum essential medium (MEM,
GIBCO) supplemented with 10 and 5% fetal bovine serum
(GIBCO), respectively, and 50µg/mL gentamycin (Thermo
Fisher Scientific).
HEK-293 cells (ATCC, CRL-1573) were grown in DMEM/F12
(GIBCO) supplemented with 10% fetal bovine serum and 50
µg/mL gentamycin.
C6/36 mosquito cell line from Aedes albopictus, was cultured
in L-15 medium (Leibovitz, GIBCO) supplemented with 0.3 %
tryptose phosphate broth (Sigma), 0.02% glutamine (Sigma), 1%
MEM non-essential amino acids solution (GIBCO) and 10% fetal
bovine serum.
DENV strains DENV-1 (Hawaii), DENV-2 (New Guinea
C), DENV-3 (H87), and DENV-4 (8,124) were provided
by Dr. A.S. Mistchenko (Hospital de Ninos Dr. Ricardo
Gutierrez, Buenos Aires, Argentina). Virus stocks were
prepared by infecting C6/36 cells with the appropriate
DENV serotype at a MOI of 0.1. Supernatants from day 3–
7 p.i. were harvested, clarified, filtered, and stored at −80◦C
until use. Quantification of the virus titers was performed
by a plaque assay (see Section 4.4 below). The titer was
expressed as the number of plaque-forming units (PFU)
per milliliter.
siRNA, Plasmid Constructs and
Transfections
For siRNA transfection, A549 cells were seeded into 24-
well microplates at a density of 1∗105 cells per well prior
to transfection using Lipofectamine 2000 (Thermo Fisher
Scientific) the following day with 50 nM siRNA (sc-36283,
Santa Cruz Biotechnology) following the manufacturer’s
specifications. Briefly, 25 pmol siRNA and 1 µl Lipofectamine
2000 was prepared in 100 µl of Opti-MEM (Thermo Fisher
Scientific), incubated at room temperature for 15min,
and then added to the cells. 48 h post transfection, cells
were used for subsequent analysis (viral infection/plaque
assays). Non-targeting scrambled siRNA (X-siRNA, sc-37007,
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FIGURE 4 | PMLIII-RFP and PMLIV-RFP colocalize with DENV-2 NS5-GFP. (A) A549 cells were co-transfected with vectors encoding one of the six PML-RFP
isoforms and DENV-2 NS5-GFP as indicated. At 24 h p.t., cells were fixed and confocal images were acquired using a Zeiss LSM710 setup. Scale bar: 10µm. (B)
Quantification of the Pearson’s coefficient was performed using FIJI. At least 10 cells per condition and per experiment were quantified. Data represent the mean ± SD
from two independent experiments, performed in triplicate.
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FIGURE 5 | Accumulation of NS5-GFP in PML-NBs overexpressing PMLIII/-IV-RFP. (A) A549 cells were cotransfected with vectors encoding for DENV-2 NS5-GFP or
nls-GFP, and PMLIII-RFP, PMLIV-RFP, or (D) mCherry-SP100 or mCherry-DAXX as indicated. At 24 h p.t., cells were fixed and confocal images were acquired using a
Zeiss LSM710 setup. Scale bar: 10µm. (B) Quantification of the mean PML-NB area in A549 cells (n > 20 for each condition and experiment) co-expressing DENV-2
NS5-GFP or nls-GFP and PMLIII- or IV-RFP was performed using FIJI. Data represent the mean ± SD from three independent experiments, each performed in
triplicate. **p < 0.01 (Student’s t test) (C,E). Quantification of the Pearson’s coefficient was performed using FIJI. At least 20 cells per condition and per experiment
were quantified. Data represent the mean ± SD from three independent experiments, each performed in triplicate. **p < 0.01 (Student’s t test).
Santa Cruz Biotechnology) was used as a negative control.
siRNA knockdown efficiency (ca. 60%) was confirmed by
qRT-PCR and indirect immunofluorescence as previously
(Giovannoni et al., 2015).
All plasmid constructs used have been described previously,
including nls-GFP, pmRFP–PML isoforms I to VI, mCherry-
SP100, mCherry-DAXX (Weidtkamp-Peters et al., 2008; Brand
et al., 2010; Ulbricht et al., 2012), DENV1-4 NS5-GFP
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FIGURE 6 | Effect of NS5 expression on PML protein levels. Western blot showing Flag-PMLIII or -PMLIV protein levels in HEK293 cells transfected to express GFP
alone (A) or NS5-GFP (B) as indicated. The day after transfection, cells were incubated with cycloheximide (CHX) for 0–8 h, prior to cell lysis, gel electrophoresis, and
Western blot analysis using the indicated antibodies. Images are representative of three independent experiments.
(Tay et al., 2013), DENV-2C (Samsa et al., 2009), and pCMV5-
Flag PMLIII, and pCMV5-Flag PMLIV (Peche et al., 2012).
For plasmid transfection, A549 cells were seeded into 24-well
microplates at a density of 1∗105 cells per well and transfected the
following day. Briefly, transfection mixture containing 0.5 µg of
plasmid DNA and 1.5µl Lipofectamine 2000 was prepared in 100
µl of Opti-MEM and incubated at room temperature for 15min
before addition to the cells. 24 h post transfection, cells were used
for downstream applications (e.g., Indirect immunofluorescence
and microscopy). Co-transfections were performed by using 0.25
µg of each plasmid DNA.
Plasmid DNA transfection into HEK-293 cells for evaluating
the antiviral effect of PML isoforms and PML-NBs components
was performed using Fugene HD (Roche). Briefly, HEK-293 cells
were seeded into 24-well plates at a density of 8∗104 cells per
well and transfected the following day. Transfection mixture
containing 0.5 µg of plasmid DNA and 1.75 µl of Fugene HD
was prepared in 100 µl of Opti-MEM and incubated at room
temperature for 15min before addition to the cells. 48 h later, cells
were used for subsequent assays (viral infection/plaque assays).
In all cases, mock transfections for either siRNA or plasmid
DNA were performed by adding the mix of transfection reagent
and Opti-MEM lacking siRNA/DNA to the cells.
Viral Infection
A549 and HEK-293 were infected at a MOI of 1. The cells
were incubated for 1 h at 37◦C prior to removal of the viral
inoculum and washing three times with PBS. Finally, fresh
medium supplemented with 2% fetal bovine serum was added.
Mock infections were performed by incubating the cells with
fresh medium instead of viral inoculum for 1 h as described.
Plaque Assay
Vero cells (2∗105 cells per well) were seeded into 24-well
microplates and grown overnight. 10-fold dilutions of samples
containing virus were added to monolayers of confluent Vero
cells at 37◦C for 1 h. Following incubation, the inoculum was
removed, and monolayers overlaid with 1ml of MEM containing
1% methylcellulose. The cells were incubated at 37◦C for 7 days
and fixed using 4% formaldehyde. Finally, plaques were stained
with 0.1% crystal violet in 20% ethanol and counted.
Indirect Immunofluorescence and
Microscopy
Cell monolayers (seeded at 2∗105 cells per well) grown on
coverslips were washed with cold PBS and fixed with 4%
formaldehyde for 10min at room temperature and permeabilized
using 0.25% Triton X-100 for 3min. Primary antibodies and
dilutions (in PBS) used were as follows: anti-PMLmAb (1:500, sc-
966, Santa Cruz Biotechnology), rabbit anti-PML (ABD-030, Jena
Biosciences, and sc-5621, Santa Cruz Biotechnology), anti-E of
DENV-1, DENV-2, and DENV-3 mAb (1:300, ab9202, Abcam),
anti-E of DENV-4 mAb (1:100, NR-15534, BEI Resources,
kind gift of Dr. Itati Ibañez), rabbit anti-C DENV-2 (1:500,
kind gift of Dr. Andrea Gamarnik). After washing steps with
PBS, secondary antibodies used were: Alexa Fluor 488-anti–
mouse IgG (1:400, Thermo Fisher Scientific), Cy3-, or Cy5-anti–
rabbit IgG (1:600, Dianova). Finally, coverslips were mounted
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FIGURE 7 | PMLIII and PMLIV reduce DENV-2 viral replication. (A) HEK-293 cells were mock-transfected or transfected with nls-GFP, PML-RFP (isoforms I to VI),
mCherry-DAXX or mCherry-SP100. 48 h p.t. cells were infected with DENV-2 (MOI = 1) and 48 h later, fixed and stained for DENV envelope glycoprotein E (green or
red, as indicated in the figure). Standard fluorescence microscopy images were acquired using an Olympus BX51 setup. Scale bar: 100µm. (B) The antiviral effect of
PMLIII or PMLIV on DENV-2 virus production was quantified by plaque assay. Data represent the mean ± SD from three independent experiments, performed in
duplicate. **p < 0.01 (one-way ANOVA followed by Tukey’s post-hoc test).
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in Prolong Gold mounting medium with 4’,6-diamidino-2-
phenylindole (DAPI) (Thermo Fisher Scientific). Alternatively,
cells were stained with DAPI and mounted in a glycerol
solution containing 1,4-diazabicyclo[2, 2, 2]octane (DABCO).
Formicroscopy of fixed cells different setups were used, including
a laser-scanning confocal microscope LSM 710/ConfoCor 3 (Carl
Zeiss) or Olympus FV1000 (Olympus), a structured illumination
microscope Zeiss Apotome.2 (Carl Zeiss) or a standard widefield
fluorescence microscope Olympus BX51 (Olympus). The setup
used for acquiring images is described in each figure legend.
Image Analysis
Quantification of the average number of PML-NBs per cell
nucleus was performed using the Fiji distribution of ImageJ
(Schindelin et al., 2012). Briefly, images (Z-stacks) of random
fields of view were acquired and maximum intensity projections
generated. Each cell to be counted was selected and the
Find Maxima tool was used; at least 50 cells per condition
were analyzed in this way to give an average estimation. For
co-localization analysis, Pearson’s correlation coefficients were
calculated using the Coloc2 Plugin on Fiji, with at least 20 cells
per condition were analyzed in this way to give an average
estimation (Manders et al., 1993). For determination of PML-NB
area, maximum intensity projections were converted to grayscale,
thresholded and the Analyze Particles tool was used; with at
least 20 cells per condition analyzed in this way to give an
average estimation.
Immunoprecipitation and Western Blot
A549 cells (∼5 × 105) were infected with DENV-2 at an MOI
of 1. 48 h after infection, cells were harvested with 1% CHAPS
in TBS supplemented with protease inhibitor cocktail (Sigma).
Samples were frozen at −80◦C and thawed for three times.
After this, the samples were centrifuged (10min, 350 g) and
supernatants were incubated for 1 h at 37◦C with 2 µg of
anti-PML mAb (sc-966, Santa Cruz Biotechnology). Antigen-
antibody complexes were immobilized by rotation for 2 h at
4◦C with Protein A-Agarose Beads (Roche). The complexes
were pelleted (10min, 350 g) and the supernatant was removed.
The complexes were then washed three times with the same
buffer used for the immunoprecipitation. After the last wash,
complexes were resuspended in 50 µl of sample buffer without
β-mercaptoethanol and boiled for 5min. Finally, samples were
centrifuged and supernatants were subjected to SDS-PAGE and
Western blot.
For Western blot analysis, whole cell lysates (input) and
precipitates (IP) and prestained molecular markers (Bio-Rad
161-0318) were separated by a 12% polyacrylamide gel and
transferred to a PVDF membrane (PerkinElmer) using a semi-
dry system (Bio-rad). Membranes were blocked with TBS
containing 0.1% Tween (TBS-T) and 5% skimmed milk at
37◦C for 1 h. Then, membranes were washed with TBS-T and
incubated with rabbit anti-NS5 DENV-2 (1:1,000, kind gift of
Dr. Andrea Gamarnik) in blocking solution at 4◦C overnight.
After rinsing in TBS-T, anti-rabbit IgG HRP-linked antibody
(1:2,500, W4011, Promega) was diluted in blocking solution and
incubated with the membranes for 1 h at 37◦C. Protein bands
were visualized by a chemiluminescence detection system using
Western Lightning ECL (PerkinElmer). Finally, this protocol was
repeated for β-actin using anti- β-actinmAb (1:1,000, #4,967, Cell
Signaling) and anti-mouse IgG HRP-linked antibody (1:4,000,
A9044, Sigma).
Cycloheximide Chase Analysis of Protein
Degradation
For cycloheximide chase analysis, HEK-293T cells (4∗105 cells
per 35mm dish) were transfected with pCMV5-Flag PML III or
pCMV5-Flag PML IV (0.8 µg/p35mm) in the presence of NS5-
GFP or GFP (0.7 µg/p35mm). After 24 h, cells were incubated
with 100µM of cycloheximide (Sigma) for the indicated times.
Proteins levels were determined byWestern blot analysis. Briefly,
cells were lysed at 4◦C in cell lysis buffer TNN [100mM TrisHCl
(pH 8), 250mM NaCl, 0.5% Nonidet (NP)40, and 0.1mM
DTT], with complete protease inhibitor cocktail (Roche, Basel,
Switzerland). Protein extracts were quantified using the Pierce
BCA Protein Assay Kit (Thermo Scientific), where 20 µg/lane
was resolved by 12% SDS-PAGE, and probed with antibodies
anti-FLAG M2 monoclonal antibody (Sigma-Aldrich) or anti-
GFP following Western transfer. Images are representative of
three independent experiments.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism
software. Two sample groups were compared using student’s t
test. Groups larger than two were compared using a one-way
analysis of variance (ANOVA) followed by Tukey’s post-hoc test.
Each figure legend indicates the number of samples analyzed and
statistical test used.
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